BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

Rhea-AI Summary

BioXcel Therapeutics (Nasdaq: BTAI) announced FDA acceptance of a supplemental New Drug Application for IGALMI for at-home treatment of agitation associated with bipolar disorders or schizophrenia. The FDA set a PDUFA target action date of November 14, 2026.

According to the company, this filing targets a potential first FDA-approved at-home option and addresses up to 86 million annual episodes while the company advances commercial and launch planning.

Positive

• FDA accepted sNDA for at-home use with a PDUFA date of Nov 14, 2026
• Potential first FDA-approved at-home treatment option for agitation linked to bipolar disorders or schizophrenia
• Addresses up to 86 million annual episodes noted by the company

Negative

• Regulatory outcome is unresolved; FDA decision is pending with a Nov 14, 2026 target date
• No FDA approval yet for at-home use; commercialization depends on review outcome

News Market Reaction – BTAI

-8.96%

14 alerts

-8.96% Session close to close

+12.3% Peak Tracked

-26.0% Trough Tracked

$36.28M Market Cap

0.7x Rel. Volume

In the Apr 1 session, BTAI declined 8.96%, reflecting a notable negative market reaction. Argus tracked a peak move of +12.3% during that session. Argus tracked a trough of -26.0% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.0% in the session following this news. A negative reaction despite FDA acceptance...

Analysis

The stock moved -9.0% in the session following this news. A negative reaction despite FDA acceptance and a firm PDUFA date of November 14, 2026 would have fit a pattern where BioXcel’s shares often fell after positive clinical updates, with an average move of -10.05% on similar news. Such a decline could have reflected ongoing concerns about past financings, going-concern language, and execution risk on commercial plans rather than the merit of the regulatory step itself.

Key Figures

PDUFA date: November 14, 2026 Annual agitation episodes: 86 million

2 metrics

PDUFA date November 14, 2026 Target action date for IGALMI sNDA at-home use

Annual agitation episodes 86 million Estimated annual episodes targeted for at-home treatment

Previous Clinical trial Reports

5 past events · Latest: Mar 05 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 05	Phase 2 results	Positive	-2.4%	Positive Phase 2 BXCL501 opioid withdrawal data from Columbia-led 80-patient trial.
Jan 20	sNDA submission	Positive	+2.7%	Submission of IGALMI sNDA for at-home agitation treatment label expansion.
Sep 10	Phase 3 efficacy data	Positive	-1.7%	Positive exploratory efficacy from SERENITY At-Home Phase 3 across 2,433 episodes.
Aug 27	Phase 3 safety success	Positive	-24.4%	SERENITY At-Home Phase 3 met primary safety endpoint supporting future sNDA.
Aug 26	Trial results preview	Positive	-24.4%	Announcement of upcoming SERENITY At-Home topline data investor call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical and regulatory milestones have often been followed by negative next-day moves, with only one of five recent clinical-trial-tagged events showing a positive reaction.

Recent Company History

Over the past year, BioXcel has advanced BXCL501/IGALMI through the SERENITY At-Home Phase 3 program, leading to an sNDA submission on January 14, 2026 and now FDA acceptance with a PDUFA date of November 14, 2026. Earlier clinical updates, including positive SERENITY At-Home topline and BXCL501 opioid-withdrawal data, typically saw share price declines despite favorable results. Today’s acceptance builds directly on those trials and the prior sNDA submission, marking another step toward potential outpatient label expansion.

Key Terms

supplemental new drug application, snda, pdufa, prescription drug user fee act

4 terms

supplemental new drug application regulatory

"has accepted its supplemental New Drug Application (sNDA) for approval of IGALMI"

A supplemental new drug application is a request submitted to regulatory authorities to make changes to an existing approved medication, such as adding new uses, strengths, or formulations. For investors, it signals that a pharmaceutical company is seeking approval for new product developments or expanded applications, which can impact the company's future sales, market potential, and stock value.

snda regulatory

"The regulatory acceptance of our sNDA for IGALMI marks a key milestone"

A SNDA (Subordination, Non‑Disturbance and Attornment Agreement) is a legal pact among a property owner’s lender, the owner’s tenants, and sometimes the landlord that sets who keeps lease rights if the property is sold or a mortgage is enforced. Think of it as a rulebook that decides whether a tenant can stay and keep paying rent or must answer to a new owner after a foreclosure. For investors, an SNDA matters because it protects predictable rental income, clarifies who has priority on claims against a property, and therefore affects a property’s value and the security of related loans.

pdufa regulatory

"The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date"

PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.

prescription drug user fee act regulatory

"The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date"

A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PDUFA target action date of November 14, 2026

Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting

NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for approval of IGALMI^® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026.

“The regulatory acceptance of our sNDA for IGALMI marks a key milestone in our company’s mission to improve the lives of millions of patients suffering from agitation associated with bipolar disorders or schizophrenia, with no FDA approved treatment option for this condition in the at-home setting,” said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. “With this progress, our focus is on advancing the commercial strategy and launch plans, tackling up to 86 million annual episodes and addressing a significant unmet need for patients and their caregivers. We look forward to working with the FDA throughout the review process.”

About BioXcel Therapeutics, Inc. 

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com. 

About BXCL501 

Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI^® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer’s dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia. 

About IGALMI^® (dexmedetomidine) sublingual film

IGALMI^® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

IGALMI can cause serious side effects, including:

• Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint.
• Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations.
• Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI.
• Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours.

The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing.

These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects.

Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids.

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or medinfo@bioxceltherapeutics.com.

Please see full prescribing information at Igalmi.com.

Forward-Looking Statements 

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: potential future development of BXCL501 in opioid withdrawal; BXCL501’s potential as a “pipeline within a product”; the potential of BXCL501 to serve as a safe and effective treatment option that can help patients successfully transition to other medications the approval of IGALMI for use in the at-home setting; bringing IGALMI^® directly to patients in the at-home setting; the approval of IGALMI for use in the at-home setting; bringing IGALMI^® directly to patients in the at-home setting; use of IGALMI in approximately 70% of schizophrenia and bipolar disorder patients, regardless of agitation severity; prescribers using IGALMI either alone or in combination with existing off-label treatments for acute agitation; IGALMI replacing benzodiazepines, which may cause dependence; broad formulary coverage of IGALMI with standard adjudication controls; patients with schizophrenia and bipolar disorder using IGALMI in approximately 80% of their acute agitation episodes; evaluating go-to-market options; reimagining existing medicines and accelerating the development of innovative therapies; transforming the standard of care in neuropsychiatry and improve lives around the world. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI^®, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company’s total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI^® or the Company’s product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI^®; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 , as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at and the Investors section of the Company’s website at. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. 

Contact Information: 

Corporate/Investors 
Russo Partners 
Nic Johnson 
nic.johnson@russopartnersllc.com  
1.303.482.6405 

Media 
Russo Partners 
David Schull 
david.schull@russopartnersllc.com  
1.858.717.2310 

Source: BioXcel Therapeutics, Inc. 

FAQ

What did BioXcel Therapeutics (BTAI) announce about IGALMI on April 1, 2026?

The company announced FDA acceptance of an sNDA for at-home use of IGALMI with a PDUFA date of Nov 14, 2026. According to the company, the filing targets a potential first FDA-approved at-home treatment for agitation associated with bipolar disorders or schizophrenia.

When is the FDA decision expected for IGALMI's at-home use (BTAI)?

The FDA assigned a Prescription Drug User Fee Act target action date of November 14, 2026. According to the company, that is the regulatory milestone when the agency is expected to complete its review and rule on approval.

How large is the patient opportunity BioXcel cites for IGALMI's at-home indication (BTAI)?

BioXcel cites a target of up to 86 million annual episodes that could be addressed by an at-home treatment option. According to the company, this figure reflects the scale of agitation episodes in the indicated populations.

Does FDA acceptance of the sNDA mean IGALMI is approved for at-home use (BTAI)?

No—acceptance means the FDA will formally review the sNDA, not that approval is granted; the decision is pending by Nov 14, 2026. According to the company, the review process is ongoing and they will engage with the FDA through the review.

What is the near-term focus for BioXcel after FDA accepted the IGALMI sNDA (BTAI)?

The company is advancing commercial strategy and launch planning while the FDA conducts its review. According to the company, preparations aim to support a potential at-home launch if regulatory approval is granted.